These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30462841)

  • 1. Cost-effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea.
    Chung W; Kim KA; Jang ES; Ki M; Choi HY; Jeong SH
    J Gastroenterol Hepatol; 2019 Apr; 34(4):776-783. PubMed ID: 30462841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].
    Buti M; Domínguez-Hernández R; Oyagüez I; Casado MÁ
    Gastroenterol Hepatol; 2016; 39(7):449-57. PubMed ID: 27084669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
    Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
    J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
    Lo AO; Chan HL; Wong VW; Wong GL
    J Gastroenterol Hepatol; 2017 May; 32(5):1071-1078. PubMed ID: 28449343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
    Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
    Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
    Saab S; Gordon SC; Park H; Sulkowski M; Ahmed A; Younossi Z
    Aliment Pharmacol Ther; 2014 Sep; 40(6):657-75. PubMed ID: 25065960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
    Satsangi S; Mehta M; Duseja A; Taneja S; Dhiman RK; Chawla Y
    J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015.
    Yin S; Barker L; White JZ; Jiles RB
    J Manag Care Spec Pharm; 2019 Feb; 25(2):195-210. PubMed ID: 30698086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
    Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
    Saab S; Virabhak S; Parisé H; Johnson S; Wang A; Misurski D; Gonzalez YS; Juday T
    Adv Ther; 2016 Aug; 33(8):1316-30. PubMed ID: 27342742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients.
    Cure S; Bianic F; Gavart S; Curtis S; Lee S; Dusheiko G
    J Med Econ; 2014 Jan; 17(1):65-76. PubMed ID: 24160335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
    Saab S; Parisé H; Virabhak S; Wang A; Marx SE; Sanchez Gonzalez Y; Misurski D; Johnson S
    J Med Econ; 2016 Aug; 19(8):795-805. PubMed ID: 27063573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.
    Restelli U; Alberti A; Lazzarin A; Bonfanti M; Nappi C; Croce D
    Eur J Health Econ; 2018 Jan; 19(1):37-44. PubMed ID: 28008546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
    Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
    Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
    Hagan LM; Sulkowski MS; Schinazi RF
    Hepatology; 2014 Jul; 60(1):37-45. PubMed ID: 24677184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.
    Siebert U; Sroczynski G; Aidelsburger P; Rossol S; Wasem J; Manns MP; McHutchison JG; Wong JB
    Pharmacoeconomics; 2009; 27(4):341-54. PubMed ID: 19485429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naïve chronic hepatitis C patients in Taiwan.
    Tsai PC; Liu TW; Hsieh MH; Yeh ML; Liang PC; Lin YH; Huang CI; Huang CF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2017 Jan; 33(1):44-49. PubMed ID: 28088273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan.
    Igarashi A; Furusyo N; Ogawa E; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J
    BMJ Open; 2019 Jun; 9(6):e023405. PubMed ID: 31221866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
    Athanasakis K; Ferrante SA; Kyriopoulos II; Petrakis I; Hill M; Retsa MP; Kyriopoulos J
    Clin Ther; 2015 Jul; 37(7):1529-40. PubMed ID: 26031617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.
    Saint-Laurent Thibault C; Moorjaney D; Ganz ML; Sill B; Hede S; Yuan Y; Gorsh B
    J Med Econ; 2017 Jul; 20(7):692-702. PubMed ID: 28294645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.